A Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignant Tumors
Status:
Recruiting
Trial end date:
2023-05-31
Target enrollment:
Participant gender:
Summary
This is an open-label, dose escalation, Phase I study to evaluate the safety, tolerability,
pharmacokinetics and efficacy of IBI110 in subjects with advanced malignancies.